Lupin launches Lapatinib Tablets secures FDA approval

▴ lupin-launches-lapatinib-tablets-secures-fda-approval
Lupin launches generic version of Novartis's Tykerb Tablets

Pharma major Lupin Limited (Lupin) announced today the launch of Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma Ltd received final approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb Tablets, 250 mg, of Novartis Pharmaceutical Corporation, and are indicated in combination with:Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab

Letrozole for the treatment of postmenopausal women with hormone-receptor-positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated
Lapatinib Tablets  had annual sales of approximately USD 61 million in the U.S. (IQVIA MAT June )

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Tags : #LupinLab #LapatinibTablets #LatestFDANewsSept30 #Novartis #TykerbTablets #NatcoPharma #LatestPharmaCorporateNewsUpdateSep30 #LapatinibGenericofTykerb

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Daily Covid-19 cases in US will hit six digits soon, warns expertsOctober 24, 2020
ICMR backed Covaxin could be ready by June 2021 ; Bharat BiotechOctober 24, 2020
Sewage signals early warning of coronavirus outbreaksOctober 24, 2020
U.S. sets single-day record for COVID-19 cases during new surgeOctober 24, 2020
Expert finds limited effectiveness of convalescent plasma for covid-19 patientsOctober 24, 2020
87 year old homeopathic doctor provides home visits to COVID-19 patients in Chandrapur district of MaharashtraOctober 24, 2020
Steroids boost survival of preterm babies in low-resource settings, new study findsOctober 24, 2020
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerOctober 24, 2020
FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trialOctober 24, 2020
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological CancersOctober 24, 2020
PMI Announces Medicago to Supply Up to 76 Million Doses of Its Plant-Derived COVID-19 Vaccine CandidateOctober 24, 2020
Gujarat records 1112 new cases of COVID-19 in last 24 hoursOctober 24, 2020
2377 COVID-19 patients recovered in Odisha in last 24 hoursOctober 24, 2020
Over 70 lakh people recovered from COVID-19 infection in country so farOctober 24, 2020
Health Minister Harsh Vardhan says next three months are crucial for country in fight against COVID-19October 24, 2020
Pfizer's Hospital Business section acquires Arixa Pharma October 24, 2020
India crosses the landmark of 10 crore total testsOctober 24, 2020
Bharat Biotech to conduct Phase 3 Trials Of Covaxin On 26,000 people across 25 sitesOctober 24, 2020
Catalent launches OptiGel DR, a delayed/enteric release Softgel October 24, 2020
Health Protection Campaign to be launched soon in ChhattisgarhOctober 24, 2020